Participants

front-page-cropped-1230x400

  • Chief Development Officer, Fate Therapeutics
  • Process Development Manager, Celyad
  • Innovation Leader, Cell Therapy Technologies, GE Healthcare
  • Chief, Robotic Systems & Technology Branch, Georgia Tech Research Institute
  • Manager Cell Therapy, Invetech
  • Global Head of Business Development & Industrial Services, Miltenyi Biotec
  • Head of Process Development, Adaptimmune
  • Commercial Development, Autologous Cell Therapy, Lonza
  • Global Head of Clinical Products, Miltenyi Biotec
  • Global Head of Non-clinical Product Development, Celixir
  • Senior Research Fellow in Healthcare Translation, Department of Paediatrics, University of Oxford
  • Director Therapeutics & Cell Therapy, Fresenius Kabi
  • Global Category Manager, Cell & Gene Therapy, Novartis
  • Director Sciences & Technology, GE Healthcare (Biosafe)
  • Associate Director, Research, Development & Innovation, Scottish National Blood Transfusion Service (SNBTS)
  • Chief Technology & Manufacturing Officer, Bone Therapeutics
  • Co-Founder, Aglaris Ltd
  • Principal CMC Regulatory Policy and Strategy, Juno Therapeutics, Inc
  • Director Of Operations, Fibrocell Science
  • Senior Product Manager, Thermo Fisher Scientific
  • Chief Technical Officer, TiGenix
  • Senior R&D Scientist, Scinus Cell Expansion BV
  • Engineering & Product Development Manager, Mesoblast
  • CTO, BlueRock Therapeutics
  • Senior Director, Technical Operations, TiGenix
  • Business Manager, MaSTherCell
  • President, Nextern Medical
  • Senior Vice President, Bioprocessing & Development CMC, Adaptimmune
  • Cell Therapy Sales Specialist, GE Healthcare
  • CEO, MedCision
  • Professor in Bioprocess Systems Engineering, Advanced Centre for Biochemical Engineering, University College London (UCL)
  • Director, Regulatory Affairs, Cell & Gene Therapies, ERA Consulting (UK) Ltd
  • Head Cell & Gene Therapy Engineering, GlaxoSmithKline
  • Chief Medical Officer, Bone Therapeutics; Managing Director, mC4Tx(modified Cell for Therapeutics); Chief Commercialisation Officer and Chair of Commercialisation Committee, ISCT
  • Senior Manager Technical Operations – Enabling Technologies, bluebird bio
  • Director Cell Therapy Process Development, Medigene Immunotherapies GmbH
  • Senior Vice President, Juno Therapeutics, Inc; Managing Director, Juno Therapeutics GmbH
  • Head of Cord Blood Development, Anthony Nolan Cord Blood Centre, Nottingham
  • Group Leader Global R&T Engineering, Lonza
  • Senior Consultant, Dark Horse Consulting
  • General Manager, Wales, ReNeuron
  • Vice President, Global Manufacturing Sciences & Technology, PCT
  • Director, Supply Chain Strategy, Cell and Gene Therapy, GlaxoSmithKline
  • Associate Director Technology & Development, Kiadis Pharma
  • Business Leader, Technology Development, Manufacturing Development & GTP Services, PCT
  • Vice President Marketing & Sales, CellGenix
  • Head of Industrial Development, TxCell
  • Cell & Gene Therapy Commercial Development, Merck
  • Director of Manufacturing Facility, Qualified Person, Technischen Universität München (TUM)
  • coFounder, Aglaris Ltd
  • Commercial Cell & Gene Therapy Manager, Miltenyi Biotec
  • Head of Manufacturing Development, Oxford BioMedica
  • Senior Project Manager R&D – T cells & Immunotherapy, Miltenyi Biotec
  • QM/Head of Quality Control, GMP Facility, Charité University Hospital, Berlin
  • CEO & Co-Founder, ATVIO Biotechnology
  • Chief Commercial Officer, MedCision
  • Head of Manufacturing Development, Cell and Gene Therapy Catapult
  • Vice President Business Operations, Zenalux Biomedical
  • Head of Department, Production Metrology, Fraunhofer Institute for Production Technology
  • Director, Process Development, Autolus Ltd
  • Vice President, Scientific Affairs, TrakCel
  • Executive Vice President of Sales & Marketing, TrakCel
  • Development Manager, MaSTherCell
  • Business Manager, Bioprocess Solutions, Saint-Gobain
  • Production Manager, Gamida-Cell
  • Principal Scientist, Novartis
  • Scientific Director, Anthony Nolan, London
  • Head of Analytical Development, Cell and Gene Therapy Catapult
  • President & CEO, OriGen Biomedical
  • Cellular Therapy Project Manager, SNBTS Cellular Therapy Development Centre
  • Executive Vice President of Manufacturing, Mesoblast
  • Senior Director R&D, Fresenius Kabi
  • Head of Cell Therapy Bioprocessing, MilliporeSigma
  • Vice President, Process Development, Achilles Therapeutics
  • Vice President of Business Development, Cell Therapy, Invetech
  • Market Development Director – Pharma, OPTIMA Machinery Corporation
  • Head of Business Unit “Life Sciences Engineering”, Fraunhofer Institute for Production Technology
  • Head of Process Development, Orbsen Therapeutics Ltd
  • Head of Manufacturing Innovation, Association of the British Pharmaceutical Industry (ABPI)
  • Director, Advanced Concepts Engineering, Saint-Gobain
  • Chief of the Biosystems and Biomaterials Division, National Institute of Standards and Technology (NIST)
  • General Manager, Cell Therapy, Thermo Fisher Scientific
  • Associate Professor, Cell & Gene Therapy Bioprocessing, Department of  Biochemical Engineering, University College London
  • Technical Research & Development, Cell & Gene Therapy Unit, Novartis Pharmaceutical Corporation
  • Director, Michael G. Harris Cell Therapy & Cell Engineering Facility,Memorial Sloan Kettering Cancer Center
  • Strategic Alliances Leader, Cell Therapy, Thermo Fisher Scientific
  • Senior Process Engineer, Scinus Cell Expansion BV
  • Senior Director, Business Development, Marken
  • President & CEO, Affigen
  • Head of Strategy & Portfolio Development for Cell & Gene Therapy Manufacturing Products & Services, MilliporeSigma
  • Head Pharmaceutical Development Cell & Gene Therapy, Novartis AG
  • Chief Operating Officer & Co-founder, TC BioPharm
  • Qualified Person, TC BioPharm
  • Senior Vice President of Manufacturing, Bellicum Pharmaceuticals
  • Senior Biomedical Engineer, PCT
  • COO, Sotio
  • Vice President Global CTD Sales & Operations, Marken
  • Vice President, Technical Operations,CRISPR Therapeutics, Inc
  • Executive Vice President, Technical Operations, Cellectis
  • Director for the UK Stem Cell Bank, Division of Advanced Therapies, NIBSC, a centre of the Medicines and Healthcare Regulatory Agency (MHRA, UK)
  • General Manager Track & Trace, Laetus
  • Director of Industrialisation, Celyad
  • Head of Innovation R&D, Gene Editing & Novel Modalities, MilliporeSigma
  • Senior Manager, Business Development, PCT
  • Director of Biological Programs, Octane Medical Group
  • COO, DCPrime BV
  • Senior Lecturer, Dept. of Biochemical Engineering, University College London (UCL)
  • Chief Operating Officer, Cell and Gene Therapy Catapult
  • Vice President, CMC, Medigene AG
  • Executive Director of Quality Operations, Celgene Cellular Therapeutics